Healthcare
Live Price
Offline$4.00
+0.00% today
1Y Change
-73.51%
Window
Jun 23, 2025 → Jun 19, 2026
Coverage: 255 bars · Jun 23, 2025 → Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Surgical Science Sweden AB (publ) (SUSRF) is a Healthcare stock with a market cap of $1.67B and listed on OTC. The stock last traded around $4.00 and down 73.5% across the available one-year price window (Jun 23, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of +12.0%, EPS growth of -50.0%, a dividend yield of 0.0%. What stands out right now is revenue +12.0%, EPS -50.0%, free cash flow -24.2% with operating margin 7.6% and ROIC 1.1%. Valuation is more restrained than many high-expectation growth names at P/E 25.1 and price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SUSRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SUSRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SUSRF Max Drawdown
-81.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SUSRF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$366.8M
-54.3% YoY
FY Net Income
$86.2M
-54.1% YoY
Free Cash Flow
$24.7M
-74.0% YoY
Revenue Growth
+12.0%
EPS Growth
-50.0%
Gross Margin
63.9%
Net Margin
6.7%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 990M | 884M | 883M | 803M | 367M |
| Gross Profit | 575M | 598M | 613M | 532M | 266M |
| Operating Income | 109M | 144M | 189M | 163M | 89M |
| EBITDA | 192M | 170M | 214M | 271M | 115M |
| Net Income | 67M | 132M | 234M | 188M | 86M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 615M | 968M | 634M | 434M | 317M |
| Total Assets | 4.7B | 5.5B | 4.7B | 4.6B | 4.0B |
| Total Liabilities | 417M | 651M | 357M | 413M | 393M |
| Shareholder Equity | 4.3B | 4.8B | 4.3B | 4.2B | 3.6B |
| Total Debt | 2M | 57M | 40M | 15M | 12M |
| Net Debt | -613M | -733M | -594M | -419M | -305M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
39M
-69.8% YoY
Capital Expenditures
14M
+58.4% YoY
Free Cash Flow
25M
-74.0% YoY
Key ratios
Gross Margin
63.9%
Operating Margin
7.6%
Net Margin
6.7%
ROE
1.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.